Three FDA advisory panel members resign over approval of Alzheimer’s drug
The DOI matches its Crossref record.
Abstract
Three members of a US Food and Drug Administration (FDA) advisory committee, which advised against authorising the Alzheimer’s disease drug aducanumab because of a lack of efficacy, have resigned after the agency went ahead and approved it.1 One of those who resigned, Harvard professor of medicine Aaron Kesselheim, wrote in a letter to acting FDA commissioner Janet Woodcock that the approval of Biogen’s drug was “probably the worst drug approval decision in recent US history.” Kesselheim was joined in resignation by Mayo Clinic neurologist David Knopman and Washington University neurologist Joel Perlmutter. They were all members of the independent Peripheral and Central Nervous …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183
“Contrary to the independent committee decision, the FDA granted accelerated approval to aducanumab on June 7, 2021, leading to the resignation of three members of the PCNS committee.(20,40) The accelerated approval pathway allows patients to have early access to drugs that target a serious disease and which provide a…”
BackgroundCan we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
“Subsequently, three FDA advisory board members have resigned [92].”
Metadata
- Authors
- Mahase, E.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2021-06-11
- Volume
- 373
- Pages
- n1503
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3166011357
- Cited by
- 48
- References
- 0
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Three FDA advisory panel members resign over approval of Alzheimer’s drug. https://app.cochat.ai/papers/10.1136/bmj.n1503
- The paper
- Mahase, E. (2021). Three FDA advisory panel members resign over approval of Alzheimer’s drug. BMJ. https://doi.org/10.1136/bmj.n1503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.